Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/23905
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bazban-Shotorbani, S | - |
dc.contributor.author | Gavins, F | - |
dc.contributor.author | Kant, K | - |
dc.contributor.author | Dufva, M | - |
dc.contributor.author | Kamaly, N | - |
dc.date.accessioned | 2022-01-08T10:32:42Z | - |
dc.date.available | 2022-01-08T10:32:42Z | - |
dc.date.issued | 2021-12-04 | - |
dc.identifier | 2100092 | - |
dc.identifier.citation | Bazban-Shotorbani, S., Gavins, F., Kant, K., Dufva, M. and Kamaly, N. (2021) 'A Biomicrofluidic Screening Platform for Dysfunctional Endothelium‐Targeted Nanoparticles and Therapeutics', Advanced NanoBiomed Research, 2 (1), 2100092, pp. 1-13, doi: 10.1002/anbr.202100092. | en_US |
dc.identifier.uri | https://bura.brunel.ac.uk/handle/2438/23905 | - |
dc.description | The data that support the findings of this study are openly available in BioRXiv at https://doi.org/10.1101/2021.05.09.443301. | - |
dc.description.abstract | Copyright © 2021 The Authors. The internal surfaces of all blood and lymphatic vessels are lined with an endothelium, which tightly controls and regulates the permeability of biological molecules. A dysfunctional endothelium (Dys-En) is a hallmark of many diseases, including atherosclerosis. Dys-En in atherosclerosis leads to loss of adherens junctions between cells, thus enhancing permeability and upregulation of adhesion receptors such as vascular cell adhesion molecule 1 (VCAM-1). Both this enhanced permeability of the endothelium and associated upregulated endothelial cell surface receptors can be exploited in nanomedicine targeting to atherosclerotic plaques. However, the relationship between targeting ligand and nanoparticle (NP) size is not well understood within this context. Herein, a biomicrofluidic model of Dys-En is developed and this platform is used to screen VCAM-1 targeted NPs. Screening of NPs with varying properties under flow shows that size plays a dominant role in NP targeting, with NPs in the range of 30–60 nm showing increased targeting to Dys-En. Moreover, treatment of Dys-En-on-a-chip with Annexin A1, as a novel proresolving mediator of inflammation, results in restoration of adherens junctions and normalization of the barrier integrity. The results demonstrate utility of using “Dys-En-on-a-chip” as a screening platform for Dys-En-targeted nanomedicines and biologics. | en_US |
dc.description.sponsorship | Lundbeckfonden. Grant Number: R215-2015-4190; Imperial College London. | en_US |
dc.description.uri | https://doi.org/10.1101/2021.05.09.443301 | - |
dc.format.extent | 1 - 13 | - |
dc.format.medium | Electronic | - |
dc.language | en | - |
dc.language.iso | en_US | en_US |
dc.publisher | Wiley-VCH GmbH | en_US |
dc.rights | Copyright © 2021 The Authors. Advanced NanoBiomed Research published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.subject | Annexin A1 | en_US |
dc.subject | biomicrofluidic models | en_US |
dc.subject | dysfunctional endothelium | en_US |
dc.subject | nanoparticles | en_US |
dc.subject | VCAM-1 | en_US |
dc.title | A Biomicrofluidic Screening Platform for Dysfunctional Endothelium‐Targeted Nanoparticles and Therapeutics | en_US |
dc.type | Article | en_US |
dc.identifier.doi | https://doi.org/10.1002/anbr.202100092 | - |
dc.relation.isPartOf | Advanced NanoBiomed Research | - |
pubs.issue | 1 | - |
pubs.publication-status | Published | - |
pubs.volume | 2 | - |
dc.identifier.eissn | 2699-9307 | - |
Appears in Collections: | Dept of Life Sciences Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText.pdf | 3.24 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License